Literature DB >> 15665856

The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair.

Claus Storgaard Sørensen1, Lasse Tengbjerg Hansen, Jaroslaw Dziegielewski, Randi G Syljuåsen, Cecilia Lundin, Jiri Bartek, Thomas Helleday.   

Abstract

The essential checkpoint kinase Chk1 is required for cell-cycle delays after DNA damage or blocked DNA replication. However, it is unclear whether Chk1 is involved in the repair of damaged DNA. Here we establish that Chk1 is a key regulator of genome maintenance by the homologous recombination repair (HRR) system. Abrogation of Chk1 function with small interfering RNA or chemical antagonists inhibits HRR, leading to persistent unrepaired DNA double-strand breaks (DSBs) and cell death after replication inhibition with hydroxyurea or DNA-damage caused by camptothecin. After hydroxyurea treatment, the essential recombination repair protein RAD51 is recruited to DNA repair foci performing a vital role in correct HRR. We demonstrate that Chk1 interacts with RAD51, and that RAD51 is phosphorylated on Thr 309 in a Chk1-dependent manner. Consistent with a functional interplay between Chk1 and RAD51, Chk1-depleted cells failed to form RAD51 nuclear foci after exposure to hydroxyurea, and cells expressing a phosphorylation-deficient mutant RAD51(T309A) were hypersensitive to hydroxyurea. These results highlight a crucial role for the Chk1 signalling pathway in protecting cells against lethal DNA lesions through regulation of HRR.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15665856     DOI: 10.1038/ncb1212

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  300 in total

1.  Akt1 inhibits homologous recombination in Brca1-deficient cells by blocking the Chk1-Rad51 pathway.

Authors:  Y Jia; W Song; F Zhang; J Yan; Q Yang
Journal:  Oncogene       Date:  2012-06-04       Impact factor: 9.867

2.  Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells.

Authors:  Pei-Chih Lee; Rajesh Kakadiya; Tsann-Long Su; Te-Chang Lee
Journal:  Neoplasia       Date:  2010-05       Impact factor: 5.715

3.  Exposure to acute hypoxia induces a transient DNA damage response which includes Chk1 and TLK1.

Authors:  Isabel M Pires; Zuzana Bencokova; Chris McGurk; Ester M Hammond
Journal:  Cell Cycle       Date:  2010-07-01       Impact factor: 4.534

4.  Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.

Authors:  Meredith A Morgan; Leslie A Parsels; Lili Zhao; Joshua D Parsels; Mary A Davis; Maria C Hassan; Sankari Arumugarajah; Linda Hylander-Gans; Deborah Morosini; Diane M Simeone; Christine E Canman; Daniel P Normolle; Sonya D Zabludoff; Jonathan Maybaum; Theodore S Lawrence
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

5.  High levels of RAD51 perturb DNA replication elongation and cause unscheduled origin firing due to impaired CHK1 activation.

Authors:  Ann Christin Parplys; Jasna Irena Seelbach; Saskia Becker; Matthias Behr; Agnieszka Wrona; Camilla Jend; Wael Yassin Mansour; Simon Andreas Joosse; Horst-Werner Stuerzbecher; Helmut Pospiech; Cordula Petersen; Ekkehard Dikomey; Kerstin Borgmann
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

6.  Coupling of Homologous Recombination and the Checkpoint by ATR.

Authors:  Rémi Buisson; Joshi Niraj; Amélie Rodrigue; Chu Kwen Ho; Johannes Kreuzer; Tzeh Keong Foo; Emilie J-L Hardy; Graham Dellaire; Wilhelm Haas; Bing Xia; Jean-Yves Masson; Lee Zou
Journal:  Mol Cell       Date:  2017-01-12       Impact factor: 17.970

7.  Checkpoint kinase 2 is required for efficient immunoglobulin diversification.

Authors:  Kathrin Davari; Samantha Frankenberger; Angelika Schmidt; Nils-Sebastian Tomi; Berit Jungnickel
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

8.  Overexpression of RAD51 occurs in aggressive prostatic cancer.

Authors:  Anita Mitra; Charles Jameson; Yolanda Barbachano; Lydia Sanchez; Zsofia Kote-Jarai; Susan Peock; Nayanta Sodha; Elizabeth Bancroft; Anne Fletcher; Colin Cooper; Douglas Easton; Rosalind Eeles; Christopher S Foster
Journal:  Histopathology       Date:  2009-12       Impact factor: 5.087

9.  RTEL1 maintains genomic stability by suppressing homologous recombination.

Authors:  Louise J Barber; Jillian L Youds; Jordan D Ward; Michael J McIlwraith; Nigel J O'Neil; Mark I R Petalcorin; Julie S Martin; Spencer J Collis; Sharon B Cantor; Melissa Auclair; Heidi Tissenbaum; Stephen C West; Ann M Rose; Simon J Boulton
Journal:  Cell       Date:  2008-10-17       Impact factor: 41.582

10.  Phosphorylation-dependent interactions of BLM and 53BP1 are required for their anti-recombinogenic roles during homologous recombination.

Authors:  Vivek Tripathi; Sarabpreet Kaur; Sagar Sengupta
Journal:  Carcinogenesis       Date:  2007-11-04       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.